Wenming Chen

List of Publications by Year
in descending order

61	3,120	949033 11	182931 54
papers	citations	h-index	g-index

63	63	63	4479
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study. BMC Medicine, 2022, 20, 108.	2.3	7
2	Echocardiographyâ€defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients. Cancer Medicine, 2022, 11, 4182-4192.	1.3	3
3	Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China. Cancer Epidemiology, 2022, 78, 102168.	0.8	4
4	Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211095.	0.6	2
5	Mechanisms underlying synergism between circularized tumor necrosis factorâ€related apoptosis inducing ligand and bortezomib in bortezomibâ€sensitive or â€resistant myeloma cells. Hematological Oncology, 2022, 40, 999-1008.	0.8	4
6	Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). Leukemia, 2021, 35, 1797-1802.	3.3	14
7	Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2021, 62, 883-890.	0.6	7
8	A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China. International Journal of Hematology, 2021, 113, 422-429.	0.7	5
9	Cyclopamine sensitizes multiple myeloma cells to circularly permuted TRAILâ€induced apoptosis. Oncology Letters, 2021, 21, 295.	0.8	4
10	The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma. BioMed Research International, 2021, 2021, 1-9.	0.9	6
11	Novel Non-coding RNA Analysis in Multiple Myeloma Identified Through High-Throughput Sequencing. Frontiers in Genetics, 2021, 12, 625019.	1.1	6
12	SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma. Biomarker Research, 2021, 9, 48.	2.8	8
13	At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China. Leukemia and Lymphoma, 2021, 62, 2992-3001.	0.6	5
14	Role of radiation therapy in primary tonsil large B cell lymphoma: a SEER-based analysis. Radiation Oncology, 2021, 16, 193.	1.2	3
15	Role of CD47 in Hematological Malignancies. Journal of Hematology and Oncology, 2020, 13, 96.	6.9	76
16	What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?. Frontiers in Oncology, 2020, 10, 538126.	1.3	10
17	Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China. Cancer Medicine, 2020, 9, 7819-7829.	1.3	8
18	The 60â€kDa heat shock protein regulates energy rearrangement and protein synthesis to promote proliferation of multiple myeloma cells. British Journal of Haematology, 2020, 190, 741-752.	1.2	16

#	Article	IF	Citations
19	Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients. Annals of Hematology, 2020, 99, 1779-1791.	0.8	8
20	Clinical Analysis of Cardiac Involvement in 53ÂPatients With Multiple Myeloma Coexistent With Light Chain Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 519-525.e1.	0.2	6
21	Aberrant Expression of Mir-20a in Serum Exosomes of Multiple Myeloma Lead Abnormal Expression of HIF-1 Signaling Pathway Related Proteins. Blood, 2020, 136, 43-43.	0.6	1
22	T(4; 14) Is Not a Poor Prognostic Factor for Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation in New Drug Era. Blood, 2020, 136, 30-30.	0.6	0
23	Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma. Blood, 2020, 136, 49-50.	0.6	15
24	Genome-wide discovery and characterization of long noncoding RNAs in patients with multiple myeloma. BMC Medical Genomics, 2019, 12, 135.	0.7	5
25	1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China. Oncologist, 2019, 24, e1132-e1140.	1.9	15
26	Progress in the identification of gene mutations involved in multiple myeloma . OncoTargets and Therapy, 2019, Volume 12, 4075-4080.	1.0	26
27	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Annals of Hematology, 2019, 98, 941-949.	0.8	9
28	Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients . OncoTargets and Therapy, 2019, Volume 12, 9999-10010.	1.0	7
29	Immunoparesis recovery 1Âyear after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation. Annals of Hematology, 2019, 98, 1177-1184.	0.8	10
30	Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation. International Journal of Hematology, 2019, 109, 169-174.	0.7	12
31	Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study. Blood, 2019, 134, 3066-3066.	0.6	2
32	Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE). Blood, 2019, 134, 5577-5577.	0.6	0
33	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. Leukemia and Lymphoma, 2018, 59, 2305-2317.	0.6	18
34	Synergistic effects of rmhTRAIL and 17-AAG on the proliferation and apoptosis of multiple myeloma cells. Hematology, 2018, 23, 620-625.	0.7	8
35	A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1008-1014.	0.6	8
36	Downâ€'regulated G proteinâ€'coupled receptor kinase 6 leads to apoptosis in multiple myeloma MM1R cells. Experimental and Therapeutic Medicine, 2018, 16, 4253-4259.	0.8	1

#	Article	IF	Citations
37	Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. Cancer Chemotherapy and Pharmacology, 2017, 79, 1141-1149.	1.1	25
38	Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. Oncology Letters, 2017, 14, 3243-3248.	0.8	9
39	Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma. International Journal of Hematology, 2017, 105, 318-325.	0.7	8
40	Safety and Efficacy of Using a Single Transradial MAC Guiding Catheter for Coronary Angiography and Intervention in Patients with ST Elevation Myocardial Infarction. Journal of Interventional Cardiology, 2017, 30, 33-42.	0.5	3
41	Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis. Journal of Hematology and Oncology, 2017, 10, 169.	6.9	55
42	More frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis. Drug Design, Development and Therapy, 2016, Volume 10, 3673-3679.	2.0	10
43	Target and resistance-related proteins of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on myeloma cell lines. Biomedical Reports, 2016, 4, 723-727.	0.9	10
44	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	5.1	1,866
45	Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma. Chinese Journal of Cancer, 2016, 35, 86.	4.9	19
46	T cell receptor rearrangements in a patient with Î³-heavy chain disease: A case report. Oncology Letters, 2016, 11, 4147-4151.	0.8	0
47	Oligodendroglioma metastasis to the bone marrow mimicking multiple myeloma: A case report. Oncology Letters, 2016, 12, 351-355.	0.8	3
48	Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma. Experimental Hematology, 2016, 44, 125-131.e11.	0.2	6
49	The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis. BioMed Research International, 2015, 2015, 1-7.	0.9	6
50	Clinical characteristics of a group of patients with multiple myeloma who had two different Î» light chains by immunofixation electrophoresis: A retrospective study from a single center. Experimental and Therapeutic Medicine, 2015, 9, 1895-1900.	0.8	4
51	Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line. OncoTargets and Therapy, 2015, 8, 1603.	1.0	9
52	Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma. Oncology Letters, 2015, 10, 1171-1175.	0.8	6
53	Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma. Oncology Letters, 2015, 9, 930-936.	0.8	18
54	Acute myocardial infarction after cilostazol use in a patient with systemic lupus erythematosus. International Journal of Cardiology, 2015, 185, 81-83.	0.8	1

#	Article	IF	Citations
55	Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial. Blood, 2015, 126, 4240-4240.	0.6	3
56	Which Should be Pursued, Cumulative Dose or Dose Intensity: A Real-World Effectiveness Analysis of Bortezomib-Based First Line Treatment for Untreated Multiple Myeloma Patients. Blood, 2015, 126, 4247-4247.	0.6	1
57	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncology, The, 2014, 15, 1195-1206.	5.1	695
58	Significance of p85 expression as a prognostic factor for patients with breast cancer. Oncology Letters, 2014, 8, 1657-1661.	0.8	3
59	Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study.. Journal of Clinical Oncology, 2012, 30, 8095-8095.	0.8	9
60	Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study.. Journal of Clinical Oncology, 2012, 30, 8097-8097.	0.8	1
61	Control of angiogenesis by inhibitor of phospholipase A2. Chinese Medical Sciences Journal, 2004, 19, 6-12.	0.2	6